defibrotide has been researched along with Hypertrophy--Left-Ventricular* in 1 studies
1 other study(ies) available for defibrotide and Hypertrophy--Left-Ventricular
| Article | Year |
|---|---|
[Transcutaneous oximetry in smokers with moderate hypertension and peripheral arterial disease treated with amlodipine and defibrotide, also with total smoking cessation].
To evaluate the hemorheological influence on oxygen release after a period of 4 months of suspension from smoking and of antihypertensive treatment with amlodipine 10 mg o.d. and defibrotide 400 mg o.d. we have studied 14 smokers with II moderate hypertension (according to the World Health Organization) with hypertensive retinopathy II and slight left ventricular hypertrophy and II stage type a peripheral arterial disease according to Leriche-Fontaine classification. The total suspension for a period of 4 months from smoking associated with a Ca-antagonist such as amlodipine and an hemorheological, antithrombotic drug such as defibrotide together could bring about an improvement on the treatment of hypertension and a notable reduction in the risks linked to the complications found in hypertensives with PAOD II type a. Topics: Amlodipine; Antihypertensive Agents; Blood Gas Monitoring, Transcutaneous; Blood Viscosity; Calcium Channel Blockers; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Peripheral Vascular Diseases; Polydeoxyribonucleotides; Smoking; Smoking Cessation | 1995 |